CKF Tide Tables

CJC-1295 No DAC

Quick Facts

PropertyValue
CategoryGrowth Hormone Releasing Hormone Analog
Risk LevelModerate/High
AdministrationSubcutaneous Injection
Typical Frequency1–3 Times Daily
Estimated Half-LifeShort-Acting Peptide
Primary Research InterestPulsatile Growth Hormone Release / Recovery / IGF-1 Support
Important Disclaimer

This material is provided strictly for educational and informational purposes related to peptide research and growth hormone signaling compounds. CJC-1295 No DAC is a biologically active GHRH analog capable of significantly altering growth hormone, IGF-1, metabolic, and recovery signaling pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.

1. Reconstitution Guide

  • Vial Size: 10 mg
  • Dilutant Type: BAC Water
  • Amount of Dilutant Added: 3 mL
  • Final Concentration: 3.33 mg/mL

At this concentration:
• 100 mcg = 0.030 mL (3.0 units)
• 300 mcg = 0.090 mL (9.0 units)

2. Route of Administration

CJC-1295 No DAC is most commonly administered as a short-acting subcutaneous injectable GHRH analog.

  • Primary Route: SubQ Injection
  • Preferred Timing: Commonly administered in fasted states
  • Administration Notes: Frequently researched in conjunction with GHRP compounds and pulsatile growth hormone protocols

3. Typical Research Protocols

  • Product Strength: 3.33 mg/mL
  • Typical Delivered Amount: 100–300 mcg per dose
  • Frequency: 1–3 times daily
  • Cycle Length: 8–16 weeks on / 4–8 weeks off
  • Special Notes: Unlike the DAC version, CJC-1295 No DAC is intentionally short-acting and is commonly used to create sharper pulsatile growth hormone release rather than prolonged elevation. Because of its shorter duration, researchers frequently administer it multiple times daily and often pair it with GHRPs such as Ipamorelin, GHRP-2, or Hexarelin to amplify pulse signaling. Many users prefer fasted administration timing to help minimize insulin and blood-glucose interference with growth hormone release. Compared to CJC-1295 DAC, the No DAC version is generally discussed as producing less sustained IGF-1 elevation and potentially less water retention, though it requires substantially more frequent administration.

4. Summary

CJC-1295 No DAC is an experimental short-acting GHRH analog researched for its potential effects on pulsatile growth hormone release, recovery enhancement, IGF-1 support, and body composition pathways.

Research interest in CJC-1295 No DAC commonly centers around pulse-based growth hormone optimization, recovery support, sleep enhancement, and performance-oriented applications.

5. Mechanism of Action

CJC-1295 No DAC functions by stimulating growth hormone releasing hormone pathways to promote pulsatile growth hormone signaling.

  • Pulsatile growth hormone release signaling
  • IGF-1 pathway support
  • Recovery signaling support
  • Potential sleep-quality enhancement
  • Metabolic pathway modulation
  • Short-duration peptide activity

Unlike DAC-modified versions, the No DAC variant is specifically designed for shorter and more pulse-oriented receptor activation.

6. Potential Benefits

  • Potential increase in pulsatile growth hormone signaling
  • Enhanced recovery support
  • Possible sleep-quality improvements
  • Potential body composition support
  • Possible connective tissue recovery support
  • Potential synergistic effects with GHRP compounds

7. Potential Risks / Side Effects

Moderate/High

  • Water retention
  • Numbness or tingling
  • Fatigue
  • Potential insulin sensitivity changes
  • Elevated IGF-1 signaling
  • Possible joint discomfort
  • Injection-frequency burden due to short duration

8. Half-Life

CJC-1295 No DAC is commonly discussed as a short-acting GHRH analog designed for pulse-based administration strategies.

Its shorter duration contrasts substantially with the prolonged activity profile of the DAC-modified version.

9. Storage Information

  • Store refrigerated before and after reconstitution
  • Protect from direct light exposure
  • Avoid repeated freeze-thaw cycles
  • Maintain sterile handling practices during preparation

10. Contraindications / Warnings

  • Active cancer concerns
  • Uncontrolled diabetes
  • Pregnancy or breastfeeding
  • Known hypersensitivity to peptide compounds
  • Use alongside multiple hormone-modulating compounds without supervision

11. Research References

  • PubMed
  • NIH Publications
  • Endocrinology literature
  • Peer-reviewed growth hormone and metabolism journals